Methylprednisolone + Prednisolone + Sirolimus
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
X-Linked Myotubular Myopathy
Conditions
X-Linked Myotubular Myopathy
Trial Timeline
Dec 15, 2025 → Oct 31, 2027
NCT ID
NCT07052929About Methylprednisolone + Prednisolone + Sirolimus
Methylprednisolone + Prednisolone + Sirolimus is a phase 1/2 stage product being developed by Astellas Pharma for X-Linked Myotubular Myopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07052929. Target conditions include X-Linked Myotubular Myopathy.
What happened to similar drugs?
2 of 8 similar drugs in X-Linked Myotubular Myopathy were approved
Approved (2) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07052929 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in X-Linked Myotubular Myopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK0214 | Viking Therapeutics | Phase 1 | 26 |
| Burosumab | Kyowa Kirin | Phase 1/2 | 32 |
| Burosumab | Kyowa Kirin | Pre-clinical | 30 |
| Burosumab | Kyowa Kirin | Pre-clinical | 26 |
| Burosumab | Kyowa Kirin | Phase 2 | 35 |
| KRN23 | Kyowa Kirin | Phase 1/2 | 32 |
| KRN23 | Kyowa Kirin | Phase 3 | 40 |
| burosumab + Oral Phosphate Supplement + active vitamin D | Kyowa Kirin | Phase 3 | 40 |
| burosumab | Kyowa Kirin | Phase 3 | 40 |
| KRN23 | Kyowa Kirin | Approved | 43 |
| burosumab | Kyowa Kirin | Phase 2 | 35 |
| Burosumab | Kyowa Kirin | Phase 3 | 40 |
| KRN23 | Kyowa Kirin | Phase 1/2 | 32 |
| Placebo + KRN23 | Kyowa Kirin | Phase 1 | 29 |
| Burosumab | Kyowa Kirin | Phase 3 | 40 |
| burosumab | Kyowa Kirin | Phase 3 | 40 |
| KRN23 | Kyowa Kirin | Phase 2 | 35 |
| KRN23 | Kyowa Kirin | Phase 1 | 29 |
| KRN23 | Kyowa Kirin | Approved | 43 |
| KK8123 | Kyowa Kirin | Phase 1/2 | 39 |